Boost portfolio income in the second half of 2026 with these cheap dividend payers

CNBC screened dividend stocks yielding at least 1.5% with 20%+ upside to analyst price targets and at least 55% buy ratings, highlighting Abbott Laboratories (2.7% yield, -10% over three months, 23% upside), Accenture (5.2% yield, -35%, 40% upside), Intercontinental Exchange (1.7% yield, -20%, 58% upside), and Medtronic (3.6% yield, -8%, 19% upside). The article is broadly defensive, emphasizing income, buybacks, and valuation support amid an expensive and volatile market. Near-term price impact is limited, but the screen may support sentiment for the named stocks.

Analysis

The setup is less about “cheap dividend stocks” and more about a crowded factor reset: high-quality cash return names have been de-rated alongside duration-sensitive growth, creating a window where capital-return support can dominate until macro volatility normalizes. The key second-order effect is that these names can become natural parking spots for institutional money rotating out of expensive megacap tech, which can compress downside faster than fundamentals alone would imply. That said, the market is not pricing a simple mean reversion; it is pricing a slower growth regime, so the winners are those with visible self-help and low balance-sheet risk.

Among the group, the most interesting asymmetry is not the highest yield, but the best mix of buybacks plus underappreciated operating optionality. ACN looks like a textbook “bad tape, good business” name: if revenue timing issues are transitory, continued repurchases can materially amplify per-share growth over the next 2-4 quarters. ICE is more interesting as a sentiment special situation; the market appears to be discounting a structural threat before the revenue mix impact is proven, which creates room for a relief rally if prediction-market fears fail to show up in the core franchise.

ABT and MDT are slower-burn defensives where the main catalyst is multiple repair rather than a rapid earnings inflection. Their downside is more likely to come from guidance credibility than demand collapse, so the trade should be sized as a quality-duration hedge rather than a momentum bet. The contrarian view is that high yield here may actually be a signal of investor fatigue, but in this tape that fatigue can persist for months while the buyback/dividend stream quietly compounds total return.

Key Decisions for Investors

• Long ACN on weakness for a 1-2 quarter horizon; target a 15-20% rebound if buybacks plus AI positioning re-rate the multiple, with risk capped if revenue misses persist for another print.
• Long ICE vs short a basket of exchange/market-structure names most exposed to structural disruption; use a 3-6 month pair to express the view that prediction-market fears are overstated and the stock is pricing too much terminal risk.
• Long MDT as a defensive quality hedge, but only with a 6-12 month horizon; expect modest upside, not a fast rerating, and treat the dividend as carry while waiting for guidance confidence to rebuild.
• Own ABT as a lower-volatility core defensive, preferably funded by trimming higher-multiple healthcare exposures; this is a relative-safety trade with upside if oversold conditions persist and rates remain volatile.
• If entering the basket, favor a barbell: ACN/ICE for upside torque plus ABT/MDT for ballast, with an explicit stop if the group underperforms the market by another 5-7% over the next 4-6 weeks.